Tavo Biotherapeutics
1 known investors
Tavo Biotherapeutics develops novel treatments for glaucoma and retinal diseases, focusing on disease-modifying therapies that target the root biological mechanisms of vision loss. The company is advancing TAV-001, a topical therapy that modulates the autonomic nervous system to reduce intraocular pressure, improve blood flow to the optic nerve, and provide neuroprotection.